Skip to main content
SpringerLink
Log in

The Need for New Antifungal Drugs

  • Chapter
New Approaches for Antifungal Drugs

Abstract

Human mycoses can be categorized as superficial, localized, or disseminated. Superficial mycoses are generally confined to the skin and nails, whereas localized mycoses include infections of the gastrointestinal, genitourinary, and respiratory tracts. Disseminated, or deep, mycoses are characterized by fungal infections of the visceral organs, central nervous system (CNS), and/or generalized fungal septicemia. While the superficial infections can be a source of great discomfort, they are not lifethreatening and are generally treatable with a variety of topical (or, in the same cases, oral) antifungal agents. Representing a substantially greater therapeutic challenge are the localized and disseminated infections, as curative therapy of these diseases is inadequate. The term “localized infection” may be taken to mean less severe; however, there is significant morbidity associated with these mycoses. Both localized and disseminated infections occur almost exclusively in immunosuppressed hosts. While the source and nature of the immunosuppression impact on the susceptibility of the host to specific opportunistic infections (OI), disseminated fungal infections are among the most common complications of acquired immunodeficiency syndrome (AIDS) and of cancer chemotherapy (Bodey, 1988; Terrell and Hermans, 1987; Anaissie et al., 1989; Armstrong, 1989; Greene, 1990; Rippon, 1990).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Allendoerfer R, Marquis AJ, Rinaldi MG, Graybill JR (1991): Combined therapy with fluconazole and flucytosine in murine cryptococcal meningitis. Antimicrob Ag Chemother 35:726–729

    Article  Google Scholar 

  • Anaissie E, Bodey GP, Kantarjian H, Ro J, Vartivarian SE, Hopfer R, Hoy J, Rolston K (1989): New spectrum of fungal infections in patients with cancer. Rev Inf Dis 11:369–378.

    Article  Google Scholar 

  • Anaissie E, Hachem R, Bodey GP (1990b): Comparative activities of fluconazole, itraconazole, saperconazole, SCH 39304 and amphotericin B against disseminated F. Solani infections in mice. 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 21–24, 1990, Atlanta, GA, Abstract No. 288

    Google Scholar 

  • Anaissie E, Kontoyiannis DP, Bodey GP (1990a): Fusarial hyalohyphomycosis; clinical spectrum, prognosis and treatment. 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 21–24, 1990, Atlanta, GA, Abstract No. 1128

    Google Scholar 

  • Armstong D (1989): Problems in management of opportunistic fungal diseases Rev Inf Dis 11:1591–1599

    Article  Google Scholar 

  • Armstrong D, Gold JWM, Dryjanski J, Whimbey E, Polsky B, Hawkins C, Brown AE, Bernard E, Kiehn TE (1985): Treatment of infections in patients with the aquired immunodeficiency syndrome. Ann Intern Med 103:738–743

    Article  Google Scholar 

  • Bodey GP (1988): Topical and systemic antifungal agents. Med Clin North Amer 72:637–659

    Google Scholar 

  • Cabib E (1991): Differential inhibition of chitin synthetases 1 and 2 from Saccharomcyses cervisiae by polyoxin D and nikkomycins. Antimicrob Ag Chemother 35:170–173

    Article  Google Scholar 

  • Cairns MR (1988): Fungal infections in the acquired immunodeficiency syndrome. J Electron Microscopy Tech 8:115–131

    Article  Google Scholar 

  • Clark AM, Hufford CD (1989): Discovery and development of prototype antifungal antibiotics from higher plants: eupolauridine. 29th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17–20, 1989, Houston, TX, Abstract No. 720

    Google Scholar 

  • Clark AM, Watson ES, Khalid Ashfaq M, Hufford CD (1987): In vivo efficacy of antifungal oxoaporphine alkaloids in experimental disseminated candidiasis. Pharm Res 4:495–498

    Article  Google Scholar 

  • Cutsem JV, Van Gerven F, Janssen PAJ (1989): Oral and parenteral therapy with saperconazole (R66905) of invasive aspergillosis in normal and immunocompromised animals. Antimicrob Ag Chemother 33:2063–2068

    Article  Google Scholar 

  • Dismukes WE (1988): Cryptococcal meningitis in patients with AIDS. J Infect Dis 157:624–628

    Article  Google Scholar 

  • Dismukes WE, Cloud G, Gallis HA, Kerkering TM, Medoff G, Caraven PC, Kaplowitz LG, Fisher JF, Gregs CR, Bowles CA, Shadomy S, Stamm AM, Diasio RB, Kaufman L, Soon S-J, Backwelder WC (1987): Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med 317:334–341

    Article  Google Scholar 

  • Dismukes WE, Cloud G, Thompson S, Sugar A, Tuazon C, Kaufman D, Grieco M, Jacobson J, Powderly W, Robinson P (1989): Fluconazole (FLU) versus amphotericin B (AMS) therapy (Rx) of active cryptococcal meningitis (C. M.). 29th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17–20, 1989, Houston, TX, Abstract No. 1065

    Google Scholar 

  • Drouhet E, Dupont B (1987): Evolution of antifungal agents: past, present, and future. Rev Inf Dis 9 (suppl 1):S4–S14

    Article  Google Scholar 

  • Drutz DJ (1987): Controversies in the diagnosis and management of infectious diseases. Session V: fungal infections. Summary and Discussion. Rev Infect Dis 9:417–420

    Article  Google Scholar 

  • Ellis WG, Sobel RA, Nielsen SL (1982): Leukoencephalopathy in patients treated with amphotericin B methyl ester. J Infect Dis 146:125–137

    Article  Google Scholar 

  • Furio MM, Wordell CJ (1985): Treatment of infectious complications of acquired immunodeficiency syndrome. Clin Pharm 4:539–554

    Google Scholar 

  • Gondal JA, Swartz RP, Rahman A (1989): Therapeutic evaluation of free and liposome-encapsulated amphotericin B in the treatment of systemic candidiasis in mice. Antimicrob Ag Chemnother 33:1544–1548

    Article  Google Scholar 

  • Gordee RS, Zeckner DJ, Ellis LF, Thakkar AL, Howard LC (1984): In vitro and in vivo anti-candida activity and toxicology of LY 121019. J Antibiot 37:1054–1065

    Article  Google Scholar 

  • Grant SM, Clissold SP (1989): Intraconazole, a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 37:310–344

    Article  Google Scholar 

  • Graybill JR, Kasten SR (1984): Experimental murine aspergillosis. Comparison of amphotericin B and a new polyine antifungal drug SCH28191. Am Rev Resp Dis 129:292–295

    Google Scholar 

  • Greene SI (1990): Treatment of fungal infections in the human immunodeficiency virus-infected individual in: Antifungal Drug Therapy, Jacobs PH, Nall L, eds. Marcel Dekker, Inc. New York: pp. 237–246

    Google Scholar 

  • Hector RF, Yee E (1990): Evaluation of bay R 3783 in rodent models of superficial and systemic candidiasis, meningeal cryptococcosis and pulmonary aspergillosis 1990. Antrimicrob Ag Chemother 34:448–454

    Article  Google Scholar 

  • Holmberg K, Meyer RD (1986): Fungal infections in patients with AIDS and AIDS-related complex. Scand J Infect Dis 18:179–192

    Article  Google Scholar 

  • Hori M, Kakiki K, Misato T (1974): Interaction between polyoxin and active center of chitin synthetase. Agric Biol Chem 3:699–705

    Article  Google Scholar 

  • Hospenthal DR, Rogers AL, Mills GL (1988): Development of amphotericin B liposomes bearing antibody specific to Candida albicans. Mycopathologia 101:37–45

    Article  Google Scholar 

  • Hufford CD, Liu S-C, Clark AM, Oguntimein BO (1987): Anticandidal activity of eupolauridine and onychine, alkaloids from Cleistopholis patens. J Nat Prod 50:961–964

    Article  Google Scholar 

  • Kastrup EK, Boyd JR, eds (1980): Antifungal Agents: Amphotericin B in: Facts and Comparisons. GH Schwach, St. Louis: pp. 356–357a

    Google Scholar 

  • Kiem GR, Sibley PL, Yoon YH, Kulesza JS, Zaidi IH, Miller MM, Poutsiaka JW (1976): Comparative toxicological studies of amphotericin B methyl ester and amphotericin B in mice, rats, and dogs. Antimicrob Ag Chemother 10:687–690

    Article  Google Scholar 

  • Koltin Y (1989): Targets for antifungal drug discovery. Ann Repts Med Chem 25:141–148

    Article  Google Scholar 

  • Larsen RA, Leal MAE, Chan LS (1990): Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. Ann Intern Med 113:183–187

    Article  Google Scholar 

  • Liu S, Oguntimein B, Hufford CD, Clark AM (1990): 3-methoxysampangine, a novel antifungal copyrine alkaloid from Cleistopholis patens. Antimicrob Ag Chemother 34:529–533

    Article  Google Scholar 

  • Medoff G, Brajtburg J, Kobayashi GS, Bolard J (1983): Antifungal agents useful in therapy of systemic fungal infections. Annu Rev Pharmacol Toxicol 23:303–330

    Article  Google Scholar 

  • Meunier F (1989): New methods for delivery of antifungal agents. Rev Infect Dis 11(S7):1605–1612

    Article  Google Scholar 

  • Muller H, Furter R, Zahner H, Rast DM (1981): Metabolic products of microorganisms: 203. Inhibition of chitosomal chitin synthetase and growth of Mucor rouxii by nikkomycin Z, nikkomycin X, and polyoxin A: a comparison. Arch Microbiol 130:195–197

    Article  Google Scholar 

  • Niki Y, Bernard EM, Schmitt H-J, Tong WP, Edwards FF, Armstrong D (1990): Pharmacokinetics of aerosol amphotericin B in rats. Antimicrob Ag Chemother 34:29–32

    Article  Google Scholar 

  • Oki T (1990): The antifungal activity and mechanism of action of pradimicin. Presented in the Symposium: Therapeutic Antifungal Targets: Discovery and Application, 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 21–24, 1990, Atlanta, GA

    Google Scholar 

  • Oki T, Konishi M, Tomatsu K, Tomita K, Saitoh K-I, Tsunakawa M, Nishio M, Miyaki T, Kawaguchi H (1988): Pradimicin, a novel class of potent antifungal antibiotics. J Antibiot 41:1701–1704

    Article  Google Scholar 

  • Patterson TF, Miniter P, Dijkstra J, Szoka FC, Ryan JL, Andriole VT (1989): Treatment of experimental invasive aspergillosis with novel amphotericin B/cholesterol-sulfate complexes. J Infect Dis 159:717–724

    Article  Google Scholar 

  • Perfect JR, Wright KA, Hobbs MM, Durack DT (1989): Treatment of experimental cryptococcal meningitis and disseminated candidiasis with SCH 39304. Antimicrob Ag Chemother 33:1735–1740

    Article  Google Scholar 

  • Richardson K, Cooper K, Marriott MS, Tarbit MH, Troke PF, Whittle PJ (1990): Discovery of fluconazole, a novel antifungal agent. Rev Infect Dis 12(suppl 3):267–271

    Article  Google Scholar 

  • Ringel S (1990): New antifungal agents for the systemic mycoses. Mycopathologia 109:75–87

    Article  Google Scholar 

  • Rippon JW (1990): Therapy in the immunosuppressed host in: Antifungal Drug Therapy, Jacobs PH, Nall L, eds. Marcel Dekker, Inc, New York: pp. 247–256

    Google Scholar 

  • Sawistowska-Schroder ET, Kerridge D, Perry H (1984): Echinocandin inhibition of 1,3-β- D-glucan synthase from Candida albicans. FEBS Lett. 173:134–138

    Article  Google Scholar 

  • Schmitt HJ, Bernard EM, Hauser M, Armstrong D (1988): Aerosol amphotericin B is effective for prophylaxis and therapy in a rat model of pulmonary aspergillosis. Antimicrob Ag Chemother 32:1676–1679

    Article  Google Scholar 

  • Stein DK, Sugar AM (1989): Fungal infections in the immunocompromised host. Diagn Microbiol Infect Dis 12:221–228

    Article  Google Scholar 

  • Sugar AM, Stern JJ, Dupont B (1990): Overview: treatment of cryptococcal meningitis. Rev Infect Dis 12(S3):338–348

    Article  Google Scholar 

  • Takeuchi T, Hara T, Naganawa H, Okada M, Hamada M, Umezawa H, Gomi S, Sezaki M, Kondo S (1988): New antifungal antibiotics, benanomicins A and B from actinomycete. J Antibiot 41:807–811

    Article  Google Scholar 

  • Terrell CL, Hermans PE (1987): Antifungal agents used for deep-seated mycotic infections. Mayo Clin. Proc. 62: 1116–1128.

    Article  Google Scholar 

  • Whimbey E, Gold JWM, Polsky B, Dryjanski J, Hawkins C, Blevins A, Brannon P, Kiehn TE, Brown AE, Armstrong D (1986): Bacteremia and fungemia in patients with the acquired immunodeficiency syndrome. Ann Intern Med 104:511–514

    Article  Google Scholar 

  • Wiebe VJ, DeGregorio MW (1988): Liposome-encapsulated amphotericin B: a promising new treatment for disseminated fungal infections. Rev Infect Dis 10:1097–1101

    Article  Google Scholar 

  • Zuger A, Louie E, Holzman RS, Simberkoff MS, Rahal JJ (1986): Cryptococcal disease in patients with the acquired immunodeficiency syndrome. Ann Intern Med 104:234–240

    Article  Google Scholar 

Download references

Authors
  1. Alice M. Clark
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Microbial Molecular Biology, Bristol Myers Squibb Pharmaceutical Research Institute, 08543, Princeton, New Jersey, USA

    Prabhavathi B. Fernandes

Rights and permissions

Reprints and permissions

Copyright information

© 1992 Springer Science+Business Media New York

About this chapter

Cite this chapter

Clark, A.M. (1992). The Need for New Antifungal Drugs. In: Fernandes, P.B. (eds) New Approaches for Antifungal Drugs. Birkhäuser, Boston, MA. https://doi.org/10.1007/978-1-4899-6729-9_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-4899-6729-9_1

  • Publisher Name: Birkhäuser, Boston, MA

  • Print ISBN: 978-1-4899-6731-2

  • Online ISBN: 978-1-4899-6729-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation